One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia

References

• Regier DA, Narrow WE, Rae DS, et al. The de facto mental and addictive disorders service system. Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94
   Google Scholar
• Chue P, Tibbo P, Wright E, et al. Client and community services satisfaction with an assertive community treatment subprogram for inner-city clients in Edmonton, Alberta. Can J Psychiatry 2004;49:621-4
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• McEvoy JP. The importance of early treatment of schizophrenia. Behav Healthc 2007;27:40-3
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, et al; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-9
   PubMedGoogle Scholar
• Cramer J, Rosenheck R, Xu W, et al. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-34
   Google Scholar
• Weiden PJ, Mott T, Curico N. Recognition and management of neuroleptic non-compliance. In Shiriqui C, Nasrallah H, eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC, American Psychiatric Press, 1995
   Google Scholar
• Weiden PJ, Olfson, M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalization rates in patients with schizophrenia. Effects of second generation antipsychotics. CNS Drugs 2002;16:473-84
   PubMed Web of Science ®Google Scholar
• Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835-42
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. Am J Psychiatry 2004;161(2 Suppl):1-56. Available at http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf Accessed September 12, 2005
   Google Scholar
• Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-74
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Delea TE, Richardson E, et al. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004;7:569-84
   PubMed Web of Science ®Google Scholar
• PharMetrics Patient Centric Database 2005. www.pharmetrics.com
   Google Scholar
• U.S. Department of Labor. Bureau of Labor Statistics. Databases and Tables. Consumer Price Index – Urban Wage Earners and Clerical Workers. Medical Care Services. www.bls.gov Accessed August 8, 2008
   Google Scholar
• Wolters Kluwer Retail Claims Database (1Q 2008). www.wkhealth.com
   Google Scholar
• First Databank Pricing Data (7/1/08). www.firstdatabank.com
   Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
   PubMed Web of Science ®Google Scholar
• Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North America double-blind trial. Neuropsychopharmacology 1998;18:41-9
   PubMed Web of Science ®Google Scholar
• Bell M, Milstein R, Beam-Goulet J, et al. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis 1992;180:723-8
   Google Scholar
• Beasley Jr CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-67
   PubMed Web of Science ®Google Scholar
• Beasley Jr CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1999;14:111-23
   Google Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Fabre, LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-78
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46
   PubMed Web of Science ®Google Scholar
• Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-18
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychol 1994;151:825-35
   Google Scholar
• Arato M, O’Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15
   PubMed Web of Science ®Google Scholar
• Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998;140:173-84
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
   PubMed Web of Science ®Google Scholar
• Laupacis, A, Sackett, DL, Roberts RS. An Assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8
   PubMed Web of Science ®Google Scholar
• Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-30
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22
   Google Scholar
• Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719-23
   PubMed Web of Science ®Google Scholar
• Invega® (paliperidone ER) prescribing information. Ortho-McNeil Janssen Pharmaceuticals, Inc.
   Google Scholar
• Risperdal® (risperidone) prescribing information. Ortho-McNeil Janssen Pharmaceuticals, Inc.
   Google Scholar
• Strutton DR, Gutierrez B, Blanchette CM. Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia. Am J Health Syst Pharm 2008;65:42-8
   PubMed Web of Science ®Google Scholar